Editas Medicine (EDIT) Treasury Shares (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Treasury Shares of $595730.0 for Q4 2025, down 74.39% year-over-year from $2.3 million in Q4 2024, and down 8.67% quarter-over-quarter from $652267.0 in Q3 2025.
Editas Medicine (EDIT) Treasury Shares (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Treasury Shares for 11 consecutive years, with $595730.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Treasury Shares fell 74.39% year-over-year to $595730.0; the TTM figure through Dec 2025 stood at $595730.0 (down 74.39% YoY), while the FY2025 annual figure was $595730.0, down 74.39% from the prior year.
- Treasury Shares declined to $595730.0 in Q4 2025 per EDIT's latest filing, from $652267.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $2.7 million in Q1 2024 and bottomed at $595730.0 in Q4 2025.
- Historically, Treasury Shares has averaged $1.5 million across 5 years, with a median of $1.5 million in 2022.
- Annual changes were most pronounced in 2022 — Treasury Shares surged 138.43% — and 2025, when it tumbled 74.39%.
- Editas Medicine's Treasury Shares stood at $628732.0 in 2021, then soared by 138.43% to $1.5 million in 2022, then jumped by 40.56% to $2.1 million in 2023, then climbed by 10.41% to $2.3 million in 2024, then sank by 74.39% to $595730.0 in 2025.
- Business Quant data shows EDIT's Treasury Shares at $595730.0 in Q4 2025, $652267.0 in Q3 2025, and $923539.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 595,730.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 595,730.00 |
| Dec 31, 2025 | 595,730.00 |
| Sep 30, 2025 | 652,267.00 |
| Sep 30, 2025 | 652,267.00 |
| Jun 30, 2025 | 923,539.00 |
| Jun 30, 2025 | 923,539.00 |
| Mar 31, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Mar 31, 2024 | 2.73 Mn |
| Mar 31, 2024 | 2.73 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Sep 30, 2023 | 2.11 Mn |